Table 4.

Index of liver and kidney function in different groups of experimental mice at the end of the diabetic trial (mean ± SD). Different letters indicate significant differences (p < 0.05 by Duncan’s test) between treatments (n = 6).

Treatment	ALT (U/L)	AST (U/L)	TBIL (μmol/L)	CREA (μmol/L)	BUN (mmol/L)
DC	52.8± 2.17 a	145.6 ± 3.08 a	7.50 ± 0.89 a	25.8 ± 1.17 a	17.3 ± 0.99 a
NC	28.0 ± 1.84 e	99.8 ± 6.87 fg	1.00 ± 0.18 g	14.7 ± 1.36 e	9.80 ± 0.18 d
EL1	36.1 ± 2.63 cd	113.3 ± 8.10 def	1.20 ± 0.15 fg	20.8 ± 0.75 bcd	13.4 ± 0.86 b
EL2	35.9 ± 1.80 cd	94.8 ± 8.59 g	1.02 ± 0.02 g	19.2 ± 1.94 cd	12.6± 1.08 bc
EL3	35.1 ± 3.36 d	94.5 ± 4.45 g	1.19 ± 0.18 fg	18.2 ± 2.13 d	13.1 ± 1.26 bc
EL4	36.9 ± 3.35 bcd	95.8 ± 9.05 g	1.46 ± 0.16 fg	21.0 ± 0.89 bcd	11.0 ± 1.17 cd
EL5	36.2 ± 3.38 cd	114.0 ± 7.66 de	1.38 ± 0.18 fg	21.0 ± 1.26 bcd	12.7 ± 0.26 bc
AL1	40.3 ± 4.51 bcd	130.2 ± 4.56 b	1.47 ± 0.18 fg	21.7 ± 1.86 bc	14.7 ± 0.81 b
AL2	43.4 ± 6.36 b	128.9 ± 5.30 bc	2.03 ± 0.10 ef	22.3 ± 1.21 b	14.2 ± 0.69 b
AL3	41.6 ± 1.36 bcd	123.6 ± 6.69 bcd	2.57 ± 0.28 e	22.8 ± 0.98 b	14.3 ± 0.92 b
AL4	43.1± 5.16 b	125.8 ± 4.16 bcd	4.87 ± 0.17 bc	21.8 ± 1.17 bc	14.2 ± 1.17 b
AL5	40.0 ± 3.19 bcd	115.5 ± 6.08 cde	3.63 ± 0.21 d	21.2 ± 0.98 bc	14.2 ± 1.32 b
MHT	42.4 ± 2.06 bc	121.1± 6.06 bcde	5.60 ± 0.55 b	21.0 ± 1.67 bcd	14.3 ± 0.76 b
XKP	43.5 ± 2.39 b	108.2 ± 8.57 efg	4.41 ± 0.22 cd	22.0 ± 1.79 bc	13.9 ± 0.82 b